N/A
Completed N=299
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
Source: ClinicalTrials.gov NCT02595450 ↗Enrolled (actual)
299
Serious AEs
4.8%
Results posted
Jan 2016
Primary outcomePrimary: Progression-free Survival (PFS) Time — 4.87 months
Summary
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (PFS) Time |
4.87 | — |
| PRIMARY Percentage of Participants With Best Overall Response |
0.92; 15.14; 63.76; 12.39 | — |
| SECONDARY Overall Survival (OS) Time |
NA | — |
Eligibility Criteria
Inclusion Criteria
- It is the physician's decision to prescribe erlotinib in participants and to document their treatment
- Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label
Exclusion Criteria
- Participants will be excluded if safety concerns occurred
- If the participant was not compliant or if the participant would wish to stop erlotinib therapy
Data sourced from ClinicalTrials.gov (NCT02595450). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.